Managing Sleep Apnea Long-Term: Cardiovascular Protection and Beyond
The cardiovascular protection afforded by CPAP therapy operates through multiple parallel mechanisms. CPAP eliminates the repetitive sympathetic nervous system surges that occur with each apneic event, reducing 24-hour urinary catecholamine levels and lowering both nocturnal and daytime blood pressure. CPAP restores normal sleep architecture — particularly slow-wave and REM sleep — allowing the complete cardiovascular repair processes that occur during deep sleep to proceed normally. CPAP reduces systemic inflammation (CRP falls significantly), improves endothelial function (flow-mediated dilation improves), reduces platelet aggregation, and normalizes the cortisol rhythm that chronic sleep fragmentation disrupts. Collectively, these mechanisms explain the cardiovascular risk reductions documented in multiple long-term cohort studies.
Metabolic consequences of sleep apnea extend well beyond cardiovascular risk. Untreated OSA produces insulin resistance through multiple pathways: intermittent hypoxia activates HIF-1 alpha signaling that upregulates gluconeogenesis, sleep fragmentation increases cortisol and growth hormone patterns that oppose insulin action, and REM sleep deprivation specifically impairs glucose metabolism. Meta-analyses consistently show CPAP therapy reduces HbA1c in diabetic patients with OSA by 0.4-0.5 percentage points — a clinically meaningful improvement comparable to some oral diabetes medications. The relationship is bidirectional: diabetes increases OSA severity through autonomic neuropathy affecting respiratory drive, and OSA worsens glycemic control through the mechanisms above.
Cognitive consequences of untreated sleep apnea are severe and clinically important. OSA causes measurable impairment in attention, working memory, executive function, and processing speed — deficits equivalent to those produced by moderate alcohol intoxication in some studies. Longitudinal data shows that OSA accelerates cognitive decline and dementia risk in older adults through multiple mechanisms: intermittent hypoxia damages hippocampal neurons, amyloid and tau accumulate in the absence of the deep sleep glymphatic clearance, and hypertension-mediated white matter damage accumulates over years. CPAP therapy partially reverses these cognitive deficits — verbal memory and attention improve significantly within 3 months of effective treatment — but this reversal may be incomplete for individuals who delay treatment for years.
Monitoring treatment effectiveness requires more than periodic equipment check-ins. Modern CPAP devices record nightly AHI on therapy, hours of use, mask leak rates, and residual central apneas — data that should be reviewed regularly with the prescribing physician. An apparently well-controlled AHI on CPAP can mask significant untreated central apneas or positional breakthrough events that maintain cardiovascular risk. Annual or biennial repeat sleep studies are appropriate for patients with significant weight changes (either gain or loss), worsening symptoms despite good CPAP adherence, or development of new cardiovascular events. The goal of long-term sleep apnea management is not the device — it is the restoration and maintenance of physiologically normal breathing throughout every night, for life.